InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,019.20
(
-0.84%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
82.04
(
-2.43%
)
Bitcoin
67,031.57
(
4.79%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 144165

Monday, 07/09/2012 10:44:44 AM

Monday, July 09, 2012 10:44:44 AM

Post# of 252642
SNY pulls Semuloparin MAA:

http://in.reuters.com/article/2012/07/09/us-sanofi-ema-idINBRE8680M920120709?feedType=RSS&feedName=health&utm_source=dlvr.it&utm_medium=twitter&dlvrit=309303

Pulling an application is SOP in the EU when regulators have concluded that a rejection is imminent. Given today’s news and the rejection of Semuloparin by an FDA advisory panel in June (#msg-76811758), it’s reasonable to presume that this drug is effectively dead.

Semuloparin, an ultra-LMW heparin, is also knows as Mulsevo, Visamerin, and AVE5026. It was once touted as SNY’s follow-on product to Lovenox.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up